News

Boeing's slow progress is not being recognized yet by the market.

Iamgold is buying back stock and has reduced its debt. A dividend might be next.

The Anthropic IPO will be delayed until November, the WSJ reported. OpenAI forecast massive negative cash flow, the FT reported.

The timing is right for this Bitcoin miner turned AI cloud provider.

The central bank just raised the federal funds rate, a move that likely didn't surprise the market.

The Oracle of Omaha stepped down from his last active role with the conglomerate, but the investment thesis is intact.

Combining different dividend stock selection strategies can produce an elite portfolio.

Cisco Systems, Inc. (NASDAQ:CSCO) is seeking to expand Splunk’s role in enterprise AI. That matters because it could give the networking giant another avenue to monetize the AI infrastructure buildout beyond hardware sales. At the 2026 Splunk conference in Denver this week (Sept. 14-17), Cisco introduced the Cisco AI POD for Splunk. This solution brings […]

What the Nvidia chief told reporters in Scotland does not match what his company put in writing last month.

Earlier this year, Nvidia invested $2 billion in semiconductor company Marvell Technology.

When financial anxiety overshadows retirement enjoyment, you know it's time to make a change.

The Nasdaq-100 is tech-heavy, but I think this high-yield consumer staples Dividend King is the best income pick.

Insider buying is a good sign for Celsius, but that's not the only thing to consider before buying the stock.

Both options are rooted in the same basic buy-and-hold philosophy, but one differs from the other in one way that's very important for the foreseeable future.

If you pay attention to history, the rate hike doesn't bode well for the markets.

Nvidia and Micron are both great options for next year.

Blockbuster IPOs rarely live up to the hype.

History may not repeat, but it rhymes.

As the market rotates away from large-cap stocks, new opportunities have emerged in their place.

Here's why Berkshire could be buying more Alphabet shares this quarter.

There has been an increase in the number of fintechs applying for bank charters.

In September 2026, Ultragenyx Pharmaceutical received full U.S. FDA approval for FAYUVI (UX111), the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, along with a Priority Review Voucher. This approval not only addresses a previously untreated ultra-rare, fatal neurodegenerative disease but also expands Ultragenyx’s commercial gene therapy portfolio and manufacturing footprint in the U.S. We’ll now explore how FAYUVI’s first-in-disease approval and the associated...

The market will be highly affected by this IPO, even if the stock isn't included in the index right away.

AGNC Investment's dividend payments have really added up over the years.

Is Arm still an under-the-radar AI winner? Wall Street is catching on fast.

It's always a smart, disciplined holding. That doesn't mean it's always immune to sweeping headwinds.

The Federal Reserve has undertaken six previous rate-hiking cycles since 1990, with each yielding highly predictable results for the stock market.

With enough time, discipline, and consistency, this strategy can get most people to the $1 million mark.

Industrywide concerns about AI development affected Micron this week.

Apple stock just got a price target cut due to the memory processor crunch.